Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,282.0
24.7 (0.76%)

 

  • STI Straits Times Index
    3,282.0
    24.7 (0.76%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,555.3
    -14.2 (-0.90%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,383.3
    -46.5 (-0.19%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,521.3
    -34.0 (-0.96%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 672.8M
  • Value: 1,088.6M
  • Rise: 129
  • Fall: 176
  • Unch: 457

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Singtel2.450+0.040
DISA0.009-
Beverly JCG0.001-
Mapletree Com Tr1.830-0.030
Thomson Medical0.086+0.002
ThaiBev0.650-
CapLand IntCom T2.010-0.020
Oceanus0.030-
Genting Sing0.785+0.010
Arion Ent0.011+0.001

World Indices

World Indices
Name Last Change
Nasdaq 14,893.8 +86.9
HSI 24,383.3 -46.5
HSCEI 8,554.8 -47.6
Jakarta 6,693.4 +35.0
Nikkei 225 28,124.3 -364.9
SSE Comp 3,521.3 -34.0
Shanghai A 3,690.0 -35.8
Shanghai B 286.8 -1.2
KOSPI 2,921.9 -40.2

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

PROMETHEUS BIOSCIENCES INC PROMETHEUS BIOSCIENCES
Updated on 14 Jan 2022 (End of trading day)
Last (USD): 35.290 Change: +5.160 High: 35.400 Remarks: -
Change (%): +17.13 Low: 29.570
Open 29.600 Yesterday's Close 30.13
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 491,084 Cumulative Value

Company Background

Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA .

Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.95374 Trailing EPS (USD) b -0.95374 NAV (USD) c 6.7310
PE a - Trailing PE d - Price / NAV c 5.2429
Dividend Yield (%) e - Cash In Hand (USD) f 7.1680 Issued & Paid-up Shares g 38,939,200
Piotroski F Score 2 Market Cap (M) 1,374.164 Free Float (%) 65.7
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i 9.928
Net Earnings Growth (%) j -24.947 Net Debt/Equity k Net Cash
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 16 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.170
-0.48 %
10 Days --4.250
-10.75 %
20 Days -+5.480
+18.38 %
Medium Term Return 3 Months -+9.340
+35.99 %
6 Months -+14.000
+65.76 %
1 Year -+8.340
+30.95 %
Long Term Return 2 Years -+8.340
+30.95 %
3 Years -+8.340
+30.95 %
5 Years -+30.340
+612.93 %
Annualised Return Annualised --
+48.12 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference PROMETHEUS BIOSCIENCES INC NASDAQ 1,374.164 - - 5.2429 -
Industry Biotechnology NASDAQ 2,349.725 106.306 114.234 4.9588 0.682
Local Peer GILEAD SCIENCES INC NASDAQ 90,026.853 731.899 12.176 4.1932 3.789
Local Peer MODERNA INC NASDAQ 83,007.779 - 11.755 8.1991 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 66,180.733 18.838 9.460 3.8348 -
Local Peer ILLUMINA INC NASDAQ 63,323.382 96.529 69.893 5.9779 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 59,510.223 21.946 27.346 6.2440 -
Local Peer BIONTECH SE SPON ADS EACH REP 1 ORD SHS NASDAQ 47,338.116 2,732.469 5.294 4.6887 -
Local Peer BIOGEN INC NASDAQ 35,151.495 8.787 22.740 3.3703 -
Local Peer SEAGEN INC NASDAQ 25,067.729 40.849 - 7.9204 -
Local Peer BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS NASDAQ 24,441.747 - - 7.2805 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 17,760.749 - - 23.4965 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 16,563.760 19.280 1,040.633 3.8826 -
Local Peer INCYTE CORPORATION NASDAQ 16,540.318 - 30.941 5.2532 -
Other Local Peers BIO-TECHNE CORP (NASDAQ), EXACT SCIENCES CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), NOVAVAX INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALKERMES PLC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ARVINAS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), INSMED INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), RECURSION PHARMACEUTICALS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), 23ANDME HOLDING CO (NASDAQ), TG THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), VERACYTE INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), VALNEVA SE SPON ADS EACH REPR 2 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), INSTIL BIO INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), IVERIC BIO INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), OLINK HLDG AB SPON ADS EACH REP 1 ORD SHS (NASDAQ), LYELL IMMUNOPHARMA INC (NASDAQ), IMMUNOGEN INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALECTOR INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), MERUS B V (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), SEER INC (NASDAQ), REGENXBIO INC (NASDAQ), INHIBRX INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ORGANOGENESIS HOLDINGS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), MOLECULAR PARTNERS AG SPON ADS EACH REP 1 ORD SHS (NASDAQ),